So the withdrawal from the market Monday of the AML drug gemtuzumab ozogamicin, marketed as Mylotarg, comes as another disappointment to those hoping for a cure. Pfizer, which makes Mylotarg ...

Pfizer’s Mylotarg looks set for a return to the US market after FDA advisers recommended its use in acute myeloid leukaemia. The drug comes with a fascinating history, and in many ways was a ...

Mylotarg (gemtuzumab/ozogamicin) is a brand-name prescription medication. It’s approved by the Food and Drug Administration (FDA) to treat certain types of acute ...

Pfizer’s Mylotarg is back on the US market after a seven-year absence, after the FDA reapproved it in the aggressive blood cancer, acute myeloid leukaemia. The world’s first approved antibody ...

Mylotarg was heralded as the first targeted therapy in the U.S. in 2000. The FDA fast-tracked its approval for leukemia, but it was withdrawn when further testing showed increased mortality.

Mylotarg (gemtuzumab ozogamicin) is a brand-name drug that’s prescribed to treat certain types of acute myeloid leukemia in adults and some children. Mylotarg is given by intravenous infusion by ...

Pfizer Inc’s (NYSE:PFE) Mylotarg is indicated for newly diagnosed CD33-positive AML in adults and relapsed or refractory AML CD33-positive acute myeloid leukemia in adults and pediatric patients ...

There was bad news and good news in a phase III trial evaluating intensive chemotherapy with or without gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia (AML) patients with newly ...

25 patients have been dosed with trem-cel and 6 patients have now received the third dose level of Mylotarg at 2 mg/m 2. On September 5, 2024, the Company provided a clinical update on 18 patients ...

100% of patients treated with trem-cel, followed by Mylotarg, achieved primary neutrophil engraftment and robust platelet recovery. Vor Bio announced a new preclinical asset, VADC45 ...